Paraplegics will Stand, Walk and Climb Stairs Using Life-Changing Assistive Device
MossRehab is Exclusive Site of the U.S. Clinical Trials of ReWalk
WHAT: The first female clinical trials patient and an experienced male user and soldier from Israel will demonstrate going
from a wheelchair to performing ambulatory functions using the ReWalk suit. ReWalk is the first commercially viable upright device that enables wheelchair users to stand, walk, and climb stairs. ReWalk can be used by people with spinal cord injury-related disabilities and eventually by others with brain injury, stroke and
other conditions that produce severe walking impairments.
MossRehab (part of Albert Einstein Healthcare Network) is the exclusive site of the U.S. clinical trials of ReWalk™. MossRehab was selected as the site for U.S. clinical trails because of its international reputation for comprehensive clinical
rehabilitation and research programs, with a special focus on medical and cognitive rehabilitation and problems with movement.
The MossRehab clinical and research staff consist of some of the world’s foremost experts in rehabilitation medicine, including
Dr. Alberto Esquenazi who was critical to the development of ReWalk.
WHO: Dr. Esquenazi, other clinical and non-clinical staff from Albert Einstein Healthcare Network, local clinical trial patient,
Israeli ReWalk user, and local politicians and dignitaries
WHEN: Tuesday, June 30
11 a.m. - noon
WHERE: MossRehab (Gait Lab)
60 Township Line Road
Elkins Park, PA
WHY: In many areas of life change comes quickly, but for the over five million mobility-impaired people in the world, little
has changed since the first folding, tubular steel wheelchair was developed in 1932. For potentially millions of wheelchair
users, ReWalk (designed by Israeli consultancy Taga for medical device company Argo Medical Technologies, Ltd.) delivers a new perspective
on the world, on themselves, and on life.
Contact: Rodney Yancey
Corporate Communications Manager
215-456-3922
yanceyr@einstein.edu
Publish date: June 26, 2009
